


**REMARKS**

In response to the outstanding restriction requirement, Applicants hereby elect to proceed with the Group II invention, without traverse. In addition, with regard to the species election, Applicants elect to proceed initially with the examination of the claims wherein TNF-alpha is the biological response modifier. Accordingly, claims 8, 9, 15, 17, 18, 19, 20 and 22 are withdrawn pending the allowability of a generic claim, at which time Applicants will reintroduce the withdrawn subject matter. Claims 5, 7, 10, 13, 14, 16, 21 and 23-29 are pending and under active examination.

The Examiner is invited to contact the undersigned attorney with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,  


David L. Parker  
Reg. No. 32,165  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201  
(512) 536-4598 (facsimile)

Date: August 5, 2005